NIH: Fogarty International Center NIH: Fogarty International Center
Advancing Science for Global Health
Advancing Science for Global Health
Home > Programs > Information > Frequently Asked Questions for applicants to Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs Print

COVID-19: COVID-19 public health information from the US CDC | COVID-19 research information from the US NIH | Español | COVID-19 resources for global health researchers

Frequently Asked Questions for applicants to Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs

Following find answers to frequently asked questions for applicants to  Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21) (PAR-19-326), released in July of 2019.

Important to note


  • Review the types of acceptable research topics under Section 1- Objectives
  • Review the guidelines for what is encompassed under interventions and under health outcomes in Section 1
  • Follow guidelines provided in Section IV.2 under PHS 398 Research Plan
  • Discuss briefly strategies for research capacity strengthening at the LMIC institution into the proposed research program

In summary, the following parts in the application should be identifiable - identify the population to work with and the stigma relevant to that population for which an intervention to reduce that stigma is being researched. Demonstrate that the use of that intervention has the stigma reducing capability and leads to a better health outcome (as defined in the RFA). Thus, the population, the type of stigma, intervention and health outcomes are strung together and reviewers must be able to identify them. Validating methods or developing new methods that could more accurately measure stigma reduction resulting in better health but must be linked to a stigma reduction intervention being contemplated.


  • Applications submitted on or after January 25, 2018 will be responsive to the new clinical trials guidelines and will need to use FORMS-E. So please make sure you are responding to FOA PAR-19-326.
  • Applications proposing studies that do not address a stigma reduction intervention strategy linked to measurement of a beneficial health outcome for HIV/AIDS may not be supported under this FOA.
  • Applications proposing refinements to or validation of stigma measurement tools should make sure to link to health outcomes which will be improved as a result of the reduction in stigma.
  • Non-U.S. based High Income Country (HIC) investigators are not eligible as PD/PIs but may be included as consultants, especially if they present special opportunities for furthering research programs. The HIC investigator cannot be a Multiple PI team member.
  • LMIC researcher / organization can be the sole applicant; however, the FOA strongly encourages collaborative proposal with at least one U.S. researcher who is identified as key personnel.
  • Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
  • New and Resubmissions are allowed for this FOA PAR 19-326. Resubmission relate to the grants that were submitted previously to PAR 17-474 but were not successful in getting funded. You are encouraged to revise in response to the Summary Statement critiques and resubmit for consideration to the new FOA PAR 19-326.
  • Allowed Indirect Costs:  PAR 19-326 will use the activity code, R21 to fund/award successful applications. The R21 mechanism is a Research Project Grant (RPG) and as such the 8% will not apply. Applicants will use their current negotiated facilities and administrative (F&A) rate applied to their modified direct cost.
  • Subcontract indirect cost are added to the total direct cost but are not used in the calculation for determining the direct “capped” cost, $125,000.00.
  • At present there are no plans to reissue this PAR.

Reviewed August 2019